文献速递心力衰竭与心肌病

白介素-1轴与急性失代偿性心力衰竭患者死亡风险

The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

本研究纳入316例急性失代偿性心力衰竭住院患者,检测入院时IL-1β和sST2水平并随访1年全因死亡率。IL-1β与sST2正相关,且高IL-1β(≥49.1 pg/ml)合并高sST2(≥35.0 ng/ml)的患者死亡风险显著增高,提示IL-1轴炎症信号可能为治疗靶点。

要点

  • ADHF患者入院IL-1β≥49.1 pg/ml与1年死亡风险增高相关(HR 2.5)。
  • IL-1β与sST2正相关(ρ=0.65),高sST2且高IL-1β者死亡风险最高(30% vs 14%)。
  • IL-1轴炎症信号可能成为ADHF治疗靶点。

核心结论

  • 循环IL-1β水平在ADHF患者中具有临床意义,并与sST2的预测能力相互作用。
  • IL-1轴相关炎症信号可能代表ADHF的治疗靶点。

研究设计与样本

  • 研究纳入316例连续住院的ADHF患者(72±12岁,57%男性,左心室射血分数45±17%)。
  • 入院时采集血样测量IL-1β和sST2水平,随访1年全因死亡率。

主要发现

  • 入院IL-1β浓度与既往心衰住院、功能受损、较高NT-proBNP和hs-TnT浓度相关。
  • 1年内死亡患者(n=52,16.5%)的IL-1β更高(p=0.005),最佳阈值为>49.1 pg/ml(HR 2.5;95%CI 1.43-4.49;p=0.0014)。
  • 循环IL-1β与sST2正相关(ρ=0.65;p<0.001)。
  • 低sST2患者IL-1β也低;高sST2患者中仅高IL-1β者死亡风险显著增高(30% vs 14%;HR 2.52;95%CI 1.40-4.56;p=0.002)。

关键数值与推荐

  • IL-1β预后阈值:≥49.1 pg/ml(HR 2.5;95%CI 1.43-4.49;p=0.0014)。
  • sST2预后阈值:≥35.0 ng/ml。

临床怎么用

  • 对ADHF患者可考虑检测入院IL-1β和sST2,联合评估1年死亡风险。
  • 高sST2且高IL-1β(≥49.1 pg/ml)患者风险最高,可能需要更密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Soluble ST2 (sST2), which is the soluble form of interleukin (IL)-1 receptor-like 1, identifies risk in acutely decompensated heart failure (ADHF). IL-1β is an inflammatory cytokine that has deleterious effects in myocardial remodeling and function. IL-1β inhibition has beneficial effects after acute myocardial infarction. However, the role of IL-1β in ADHF and its relationship to ST2 remain unclear. OBJECTIVES: This study sought to investigate the relationship between IL-1β and sST2, and the prognostic impact of such a relationship in patients with ADHF. METHODS: This study examined 316 consecutive patients who were hospitalized with ADHF (72 ± 12 years of age, 57% male, and left ventricular ejection fraction 45 ± 17%). Blood samples were collected at presentation, and IL-1β and sST2 levels were measured. All-cause mortality was obtained for all patients at 1 year. RESULTS: The IL-1β concentration at presentation was associated with prior HF hospitalizations, functional impairment, and higher N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T concentrations. IL-1β was higher in patients who died during the year after hospitalization (n = 52, 16.5%) (p = 0.005), and the optimal threshold was identified with levels over 49.1 pg/ml (hazard ratio: 2.5; 95% confidence interval: 1.43 to 4.49; p = 0.0014). Circulating IL-1β positively correlated with sST2 (ρ = 0.65; p < 0.001). Considering the prognostic thresholds of IL-1β (≥49.1 pg/ml) and sST2 (≥35.0 ng/ml) concentrations: all patients with low sST2 also presented with low IL-1β; among patients with high sST2, only those with also high IL-1β had a significantly higher risk of death (30% vs. 14%; hazard ratio: 2.52; 95% confidence interval: 1.40 to 4.56; p = 0.002). CONCLUSIONS: Circulating IL-1β concentrations are clinically meaningful in ADHF patients and interplay with the predictive ability of sST2. IL-1 axis-related inflammation signaling may represent a therapeutic target in ADHF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Pascual-Figal DA, Bayes-Genis A, Asensio-Lopez MC, et al. The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. J Am Coll Cardiol. 2019. PMID: 30846095. doi:10.1016/j.jacc.2018.11.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。